Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs

Received Priority Review and Acceptance for Filing of the NDA for Omaveloxolone for Treatment of Patients with Friedreich’s Ataxia

Provides Update from FDA Mid-Cycle Communication Meeting on Omaveloxolone for Patients with Friedreich’s Ataxia

Announces Results of New Data and Analyses Submitted to FDA

Conference Call With Management on August 8, 2022, at 8:30 a.m. ET

PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter of 2022 and provided an update on the Company’s business operations and clinical development programs.

Read the Full article here